skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy

Abstract

Uranium-230 (t1/2 = 20.8 d) is an alpha-emitting radionuclide that has potential application in targeted alpha therapy (TAT) of cancer. Its parent isotope 230Pa (t1/2 = 17.4 d), can be produced by proton irradiation of thorium metal targets. Preliminary 230Pa production runs were performed at the Los Alamos National Laboratory Isotope Production Facility (LANL-IPF) using thin thorium metal targets and a proton beam energy of 15–30 MeV, followed by radiochemical separation of 230Pa from the irradiated target matrix. The measured 230Pa production yields were found to exceed the predicted values in most of the experiments that were performed. Furthermore, this data will inform further production efforts for providing 230Pa/230U for clinical trials.

Authors:
ORCiD logo [1]; ORCiD logo [2];  [1]; ORCiD logo [1];  [1]; ORCiD logo [1]; ORCiD logo [1]; ORCiD logo [1]
  1. Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Chemistry Div.
  2. Univ. of Utah, Salt Lake City, UT (United States). Nuclear Engineering Program, Dept. of Civil and Environmental Engineering; Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Chemistry Div.
Publication Date:
Research Org.:
Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Sponsoring Org.:
USDOE Office of Science (SC), Nuclear Physics (NP)
OSTI Identifier:
1574001
Alternate Identifier(s):
OSTI ID: 1596158
Report Number(s):
LA-UR-19-28727
Journal ID: ISSN 0969-8043; TRN: US2001112
Grant/Contract Number:  
89233218CNA000001; FOA LAB 14-1099
Resource Type:
Journal Article: Accepted Manuscript
Journal Name:
Applied Radiation and Isotopes
Additional Journal Information:
Journal Volume: 156; Journal ID: ISSN 0969-8043
Publisher:
Elsevier
Country of Publication:
United States
Language:
English
Subject:
07 ISOTOPE AND RADIATION SOURCES; Protactinium-230; Uranium-230; Thorium-226; Proton irradiation; Isotope production; Targeted alpha therapy

Citation Formats

Friend, Mitchell Thomas, Mastren, Tara, Parker, Tracey Gannon, Vermeulen, Christiaan E., Brugh, Mark, Birnbaum, Eva R., Nortier, Francios Meiring, and Fassbender, Michael Ernst. Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy. United States: N. p., 2019. Web. doi:10.1016/j.apradiso.2019.108973.
Friend, Mitchell Thomas, Mastren, Tara, Parker, Tracey Gannon, Vermeulen, Christiaan E., Brugh, Mark, Birnbaum, Eva R., Nortier, Francios Meiring, & Fassbender, Michael Ernst. Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy. United States. https://doi.org/10.1016/j.apradiso.2019.108973
Friend, Mitchell Thomas, Mastren, Tara, Parker, Tracey Gannon, Vermeulen, Christiaan E., Brugh, Mark, Birnbaum, Eva R., Nortier, Francios Meiring, and Fassbender, Michael Ernst. 2019. "Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy". United States. https://doi.org/10.1016/j.apradiso.2019.108973. https://www.osti.gov/servlets/purl/1574001.
@article{osti_1574001,
title = {Production of 230Pa by proton irradiation of 232Th at the LANL isotope production facility: Precursor of 230U for targeted alpha therapy},
author = {Friend, Mitchell Thomas and Mastren, Tara and Parker, Tracey Gannon and Vermeulen, Christiaan E. and Brugh, Mark and Birnbaum, Eva R. and Nortier, Francios Meiring and Fassbender, Michael Ernst},
abstractNote = {Uranium-230 (t1/2 = 20.8 d) is an alpha-emitting radionuclide that has potential application in targeted alpha therapy (TAT) of cancer. Its parent isotope 230Pa (t1/2 = 17.4 d), can be produced by proton irradiation of thorium metal targets. Preliminary 230Pa production runs were performed at the Los Alamos National Laboratory Isotope Production Facility (LANL-IPF) using thin thorium metal targets and a proton beam energy of 15–30 MeV, followed by radiochemical separation of 230Pa from the irradiated target matrix. The measured 230Pa production yields were found to exceed the predicted values in most of the experiments that were performed. Furthermore, this data will inform further production efforts for providing 230Pa/230U for clinical trials.},
doi = {10.1016/j.apradiso.2019.108973},
url = {https://www.osti.gov/biblio/1574001}, journal = {Applied Radiation and Isotopes},
issn = {0969-8043},
number = ,
volume = 156,
place = {United States},
year = {2019},
month = {11}
}